Medical Devices

Biopharma veteran Glenn Gormley joins Aktis's board, bringing deep ADC expertise to guide the company's next-gen radiopharmaceutical pipeline.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.

Rapid Medical's new TIGERTRIEVER 25 gains FDA clearance, offering doctors unprecedented real-time control to remove large, complex clots in stroke patients.

An FDA-approved system lets surgeons see residual cancer in real-time during lumpectomies, offering new hope for avoiding the dreaded second surgery.

A new clinical trial validates the Leva Pelvic Health System, offering a discreet, effective at-home treatment for a condition affecting millions of women.

With a massively oversubscribed €600M hybrid note offering, plant-based leader Roquette secures major funding and a huge vote of investor confidence.

A new AI platform is revolutionizing how pharma creates complex scientific videos, earning industry award recognition for its speed, savings, and compliance.

A new oral therapy shows a 76% response rate in a hard-to-treat lung cancer, offering a powerful new first-line option for patients with this rare disease.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

Backed by Arcline, engineered components maker Arxis launches a blockbuster IPO, signaling strong investor faith in aerospace, defense, and med-tech.

PROLLENIUM launches its PACE digital portal, using AI, gamification, and evidence-based methods to set a new standard for aesthetic practitioner education.

A new AI platform is the first to get EU approval for predicting fertility treatment timing, promising to boost success rates and ease clinic workloads.

With 62 profitable quarters and a major new acquisition, BioSyent prepares to pitch its proven growth strategy to top healthcare investors in Toronto.

A new biotech player is advancing a first-in-class cancer drug that combines two payloads to fight tumors that have become resistant to current therapies.

A CEO's personal battle with prostate cancer inspired a community golf tournament that is now on the verge of raising $1 million for critical research.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A first-in-class AI software, neuropacs™, gains FDA clearance, promising to help doctors differentiate complex Parkinsonian syndromes with high accuracy.

A new minimally invasive implant could revolutionize prosthetic control. Phantom Neuro's human trial in Australia marks a major step forward for amputees.